• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies
CONCLUSIONS: This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States.PMID:37584187 | DOI:10.1080/03007995.2023.2247988
Source: Current Medical Research and Opinion - August 16, 2023 Category: Research Authors: William L Baker Matthew S Roberts Youssef Bessada Kimberly S Caroti Veronica Ashton Brahim K Bookhart Craig I Coleman Source Type: research

Mechanisms of COVID-19-induced cerebellitis
Curr Med Res Opin. 2022 Oct 28:1-25. doi: 10.1080/03007995.2022.2141963. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by SARS-CoV2 has raised several important health concerns, not least increased mortality and morbidity. SARS-CoV2 can infect the central nervous system via hematogenous or transneuronal routes, acting through different receptors including ACE2, DPP4 and neuropilin 1- and cause several issues, include the focus here, cerebellitis. The cerebellum is an essential part of the CNS located adjacent to the brainstem with a complex micro and macroscopic structure. The cerebellum plays several physiolo...
Source: Current Medical Research and Opinion - October 28, 2022 Category: Research Authors: Mohammad Banazadeh Sepehr Olangian-Tehrani Melika Sharifi Mohammadreza Malek-Ahmadi Farhad Nikzad Nooria Doozandeh-Nargesi Alireza Mohammadi Gary J Stephens Mohammad Shabani Source Type: research

Payer Formulary exclusions of apixaban: how patients respond and potential implications
Curr Med Res Opin. 2022 Sep 26:1-10. doi: 10.1080/03007995.2022.2128189. Online ahead of print.ABSTRACTIn recent years, U.S. payers have increased usage of formulary exclusions as a means to help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the country added Eliquis (apixaban), the most widely used anticoagulant, to its list of excluded medicines from its formulary, raising concerns by physicians and patients. In this commentary, we examine the potential impacts of formulary exclusion of a drug like apixaban-a treatment for patients with atrial fibrillation and venous thromboembolism to ...
Source: Current Medical Research and Opinion - September 27, 2022 Category: Research Authors: Steven Deitelzweig Emi Terasawa Amiee Kang Nipun Atreja Dionne M Hines Ahmed Noman Xuemei Luo Source Type: research

Impact of apixaban treatment discontinuation on the risk of hospitalization among patients with nonvalvular atrial fibrillation and COVID-19
CONCLUSION: NVAF patients with COVID-19 who discontinued apixaban had a higher risk of hospitalization and thrombotic events vs. those who continued apixaban, with no significant difference in bleeding-related hospitalization.PMID:36000258 | DOI:10.1080/03007995.2022.2112871
Source: Current Medical Research and Opinion - August 24, 2022 Category: Research Authors: Steven Deitelzweig Julia Zhu Jenny Jiang Xuemei Luo Allison Keshishian Mauricio Ferri Lisa Rosenblatt Patricia Schuler Cynthia Gutierrez Amol D Dhamane Source Type: research

Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation and Valvular Heart Disease.
CONCLUSIONS: NOACs had a comparable risk of ischemic stroke and bleeding in patients with AF and VHD, and reduced the risk of venous thromboembolism, intracranial hemorrhage, and mortality, compared to warfarin. Therefore, NOAC is an effective and safe alternative to warfarin in these patients. PMID: 33538623 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research

Minor bleeding in patients with atrial fibrillation using a non-vitamin K antagonist oral anticoagulant.
Conclusion: Our data showed that minor bleeds are common in novel NOAC users, especially when using apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more frequently observed and accounted for the difference with dabigatran. Besides type of NOAC, a higher HAS-BLED score and novel anticoagulant drug use were associated with an increased risk of minor bleeding. PMID: 32573287 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 24, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban. PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
CONCLUSIONS: In this large practice-based population of AF patients prescribed OACs for primary prevention of stroke and systemic embolization, subsequent risk of VTE was lowest among those prescribed apixaban and dabigatran, while risk was similar with prescriptions for warfarin and rivaroxaban. Among AF patients prescribed OACs, lowering risk of VTE may be an additional benefit of apixaban and dabigatran, beyond the reduced bleeding risk observed in randomized clinical trials. PMID: 30362847 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - October 27, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban.
CONCLUSION: A favorable clinical profile with rivaroxaban was observed across age subgroups, supporting the premise that dosing in older adults does not necessitate adjustment. However, it is prudent that a cautious and individualized approach is taken for treatment with any anticoagulant in older adults. PMID: 29932775 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 28, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

Pages: 1  2